ATE420965T1 - Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren - Google Patents

Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren

Info

Publication number
ATE420965T1
ATE420965T1 AT05751967T AT05751967T ATE420965T1 AT E420965 T1 ATE420965 T1 AT E420965T1 AT 05751967 T AT05751967 T AT 05751967T AT 05751967 T AT05751967 T AT 05751967T AT E420965 T1 ATE420965 T1 AT E420965T1
Authority
AT
Austria
Prior art keywords
particles
derived
methods
alphavirus vectors
arps
Prior art date
Application number
AT05751967T
Other languages
English (en)
Inventor
Jon Rayner
Jonathan Smith
Bolyn Hubby
Elizabeth Reap
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Application granted granted Critical
Publication of ATE420965T1 publication Critical patent/ATE420965T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05751967T 2004-05-18 2005-05-18 Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren ATE420965T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57221204P 2004-05-18 2004-05-18

Publications (1)

Publication Number Publication Date
ATE420965T1 true ATE420965T1 (de) 2009-01-15

Family

ID=34970550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05751967T ATE420965T1 (de) 2004-05-18 2005-05-18 Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren

Country Status (16)

Country Link
US (5) US20050266550A1 (de)
EP (1) EP1751289B1 (de)
JP (1) JP5065024B2 (de)
CN (1) CN1989250B (de)
AT (1) ATE420965T1 (de)
AU (1) AU2005245956B2 (de)
CA (1) CA2567254C (de)
DE (1) DE602005012382D1 (de)
DK (1) DK1751289T3 (de)
ES (1) ES2321212T3 (de)
IL (1) IL178917A (de)
MX (1) MXPA06013124A (de)
NZ (1) NZ550818A (de)
PT (1) PT1751289E (de)
WO (1) WO2005113782A1 (de)
ZA (1) ZA200610561B (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
EP2066346B1 (de) 2006-09-12 2019-07-03 AlphaVax, Inc. Für il-12 kodierende alphavirusreplikationspartikel als immunologische hilfsstoffe
WO2008033966A2 (en) 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
NZ582495A (en) 2007-06-21 2012-05-25 Alphavax Inc Promoterless cassettes for expression of alphavirus structural proteins
WO2009048633A2 (en) * 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
WO2009051707A1 (en) * 2007-10-15 2009-04-23 Duke University Vaccine vectors
US20100010888A1 (en) * 2008-07-14 2010-01-14 Richard Maertz Methods and systems for offering purchase incentives
WO2010065414A1 (en) 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
ES2540958T3 (es) 2009-04-08 2015-07-15 Alphavax, Inc. Partículas de replicón de alfavirus que expresan TRP2
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
CN103154242B (zh) 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
HRP20221048T1 (hr) 2010-08-31 2022-11-11 Glaxosmithkline Biologicals Sa Mali liposomi za isporuku rna koja kodira imunogen
EP3520813B1 (de) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigenfreisetzungsplattformen
US10004797B2 (en) * 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
EP3854413A1 (de) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
US20140255472A1 (en) 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
CN109045294A (zh) 2013-01-10 2018-12-21 思齐乐 流感病毒免疫原性组合物及其应用
US11155572B2 (en) 2013-03-15 2021-10-26 Glaxosmithkline Biologicals Sa RNA purification methods
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
EP3798229A1 (de) 2014-03-25 2021-03-31 Yale University Verwendung von migrationshemmungsfaktoren parasitärer makrophagen
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CA2960102C (en) 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
WO2017123652A1 (en) 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
US10538786B2 (en) 2016-04-13 2020-01-21 Janssen Pharmaceuticals, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2017208191A1 (en) 2016-06-02 2017-12-07 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
EP3518966A1 (de) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Zusammensetzungen und verfahren zur behandlung von persistenten hpv-infektionen
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018091540A1 (en) 2016-11-17 2018-05-24 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
CA3045650A1 (en) 2016-12-05 2018-06-14 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
WO2018194890A1 (en) * 2017-04-19 2018-10-25 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
EP3461497A1 (de) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Virale antigene
JP7472019B2 (ja) * 2017-11-06 2024-04-22 インターベット インターナショナル ベー． フェー． 狂犬病ウイルスワクチン
JP7731670B2 (ja) * 2017-11-06 2025-09-01 インターベット インターナショナル ベー． フェー． ネコ白血病ウイルスワクチン
BR112020008958A2 (pt) 2017-11-06 2021-05-11 Intervet International B.V. vacina contra calicivírus felino
WO2019110213A1 (en) * 2017-12-08 2019-06-13 Intervet International B.V. Feline calicivirus vaccine
US11167027B2 (en) 2017-11-06 2021-11-09 Intervet Inc. Multivalent feline vaccine
WO2019115090A1 (en) 2017-12-15 2019-06-20 Intervet International B.V. Multivalent feline vaccine
EP3720488A1 (de) 2017-12-04 2020-10-14 Intervet International B.V. Impfung mit replikonpartikeln und öladjuvanz
JP7825939B2 (ja) * 2017-12-04 2026-03-09 インターベット インターナショナル ベー． フェー． イヌライム病ワクチン
JP7346417B2 (ja) 2017-12-18 2023-09-19 インターベット インターナショナル ベー． フェー． ブタインフルエンザａウイルスワクチン
WO2019124441A1 (en) 2017-12-20 2019-06-27 Vlp Therapeutics, Llc Alphavirus replicon particle
BR112020014525A2 (pt) 2018-01-19 2020-12-08 Janssen Pharmaceuticals, Inc. Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
CN113164584A (zh) 2018-08-17 2021-07-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物及其用途
US12331076B2 (en) 2018-10-08 2025-06-17 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
CN113194989B (zh) 2018-12-20 2024-01-30 英特维特国际股份有限公司 初免-强化免疫接种方案
CN109784705B (zh) * 2019-01-02 2021-07-02 中国石油天然气股份有限公司 预测产油量的方法、装置及存储介质
AU2020318680B2 (en) 2019-07-21 2025-04-24 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
US11730799B2 (en) 2019-10-18 2023-08-22 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
EP4126021A1 (de) 2020-03-23 2023-02-08 HDT Bio Corp. Zusammensetzungen und verfahren zur abgabe von rna
EP4135761A1 (de) 2020-04-16 2023-02-22 GlaxoSmithKline Biologicals S.A. Sars-cov-2-spike-proteinkonstrukt
EP4135847A4 (de) * 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus-impfstoff
CA3174651A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
WO2021228731A1 (en) * 2020-05-11 2021-11-18 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
BR112022024932A2 (pt) 2020-06-19 2022-12-27 Intervet Int Bv Vacina contra vírus da influenza a suína compreendendo um constructo de ácido nucleico que possui uma ordem específica de genes
US20230277649A1 (en) 2020-06-19 2023-09-07 Intervet Inc. Swine influenza a virus vaccine comprising two distinct rna replicon particles
WO2021255225A1 (en) 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
JP2023530135A (ja) 2020-06-19 2023-07-13 インターベット インターナショナル ベー． フェー． 特定のウイルス系統の抗原をエンコードする核酸構築物を含むブタインフルエンザａウイルスワクチン
BR112022025653A2 (pt) 2020-06-19 2023-03-07 Ziphius Vaccines Vacina autoamplificante de rna sars-cov-2
WO2022002783A1 (en) 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
PH12023550070A1 (en) * 2020-07-10 2024-03-11 Boehringer Ingelheim Int Process for producing a purified rhabdovirus from cell culture
CN116171150A (zh) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 冻干脂质纳米颗粒的方法
US20220193225A1 (en) * 2020-08-31 2022-06-23 Bruce Lyday Compositions and methods for sars-2 vaccine with virus replicative particles and recombinant glycoproteins
WO2022049276A1 (en) 2020-09-07 2022-03-10 Intervet International B.V. Ha stem vaccine for ha antibody-positive targets
TW202233232A (zh) 2020-11-06 2022-09-01 法商賽諾菲公司 遞送mRNA疫苗的脂質奈米顆粒
JP2023549787A (ja) 2020-11-12 2023-11-29 インターベット インターナショナル ベー． フェー． キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
EP4267593A2 (de) 2020-12-23 2023-11-01 GlaxoSmithKline Biologicals SA Selbstverstärkende messenger-rna
EP4032546A1 (de) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Therapeutischer viraler impfstoff
IL319926A (en) * 2021-03-19 2025-05-01 Tiba Biotech Llc Alphavirus-derived artificial RNA replicon expression systems
US20240181038A1 (en) 2021-03-26 2024-06-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20240285755A1 (en) 2021-05-24 2024-08-29 Glaxosmithkline Biologicals Sa Adjuvants
KR20240022610A (ko) 2021-06-18 2024-02-20 사노피 다가 인플루엔자 백신
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
US20240350410A1 (en) 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
CN118043466A (zh) 2021-09-03 2024-05-14 葛兰素史克生物有限公司 自扩增信使核糖核酸中核苷酸碱基的取代
KR20240088845A (ko) 2021-09-22 2024-06-20 에이치디티 바이오 코포레이션 건조된 나노입자 조성물
KR20240111819A (ko) 2021-09-22 2024-07-17 에이치디티 바이오 코포레이션 암 치료 조성물 및 이들의 용도
CA3232658A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Rna vaccines against infectious diseases
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
US20250281597A1 (en) 2021-10-25 2025-09-11 Intervet Inc. A vaccine for the protection of piglets against swine influenza a virus infection
ES3048411T3 (en) 2021-11-02 2025-12-10 Ziphius Nv Lipid nanoparticles for oligonucleotide delivery
US20250236599A1 (en) 2021-11-02 2025-07-24 Ziphius Nv Lipid nanoparticles for oligonucleotide delivery
WO2023078954A1 (en) 2021-11-02 2023-05-11 Ziphius Vaccines Nv Lipid nanoparticles for oligonucleotide delivery
KR20240107146A (ko) 2021-11-05 2024-07-08 사노피 호흡기 세포융합 바이러스 rna 백신
CA3242439A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
US11730804B1 (en) * 2022-04-13 2023-08-22 Replicate Bioscience, Inc. Compositions and methods for the prevention and treatment of rabies virus infection
CA3256624A1 (en) 2022-05-06 2023-11-09 Sanofi SIGNAL SEQUENCES FOR NUCLEIC ACID-BASED VACCINES
CA3265295A1 (en) 2022-08-22 2024-02-29 United States Of America, As Represented By The Secretary, Department Of Health And Human Services CORONAVIRUS VACCINES
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
JP2025541298A (ja) 2022-12-15 2025-12-18 サノフィ パスツール インコーポレイテッド ｍＲＮＡ組換えキャッピング酵素
CN120456919A (zh) 2022-12-19 2025-08-08 葛兰素史克生物有限公司 乙型肝炎组合物
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
WO2024180262A1 (en) 2023-03-02 2024-09-06 Sanofi Compositions for use in treatment of chlamydia
IL324411A (en) 2023-05-05 2026-01-01 Sanofi Pasteur Inc Preparations for use in the treatment of acne
WO2024231565A1 (en) 2023-05-10 2024-11-14 Sanofi Combination respiratory mrna vaccines
WO2025017202A2 (en) 2023-07-19 2025-01-23 Sanofi Porphyromonas gingivalis antigenic constructs
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
WO2025172320A1 (en) 2024-02-12 2025-08-21 Universiteit Gent Enhanced self-amplifying or trans-amplifying rna
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026018213A1 (en) 2024-07-18 2026-01-22 Vaxthera Sas A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
WO2026037537A1 (en) 2024-08-16 2026-02-19 Intervet International B.V. Canine influenza virus vaccine

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
WO1994017813A1 (en) * 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
EP0694070B1 (de) 1993-09-15 2002-04-10 Chiron Corporation Rekombinanter alphavirus vektor
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5639650A (en) * 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CZ438398A3 (cs) * 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) * 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
JP4492826B2 (ja) * 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) * 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
AU754320B2 (en) 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer
EP1080218A1 (de) * 1998-05-27 2001-03-07 University of Florida Methode zur darstellung von rekombinanten adeno-assoziierten virus zusammensetzungen mit hilfe von iodixanol gradienten
EP1119626B1 (de) * 1998-07-10 2008-01-02 U.S. Army Medical Research Institute of Infectious Diseases Impfstoffe gegen neurotoxine von clostridium botulinum
JP3585778B2 (ja) * 1998-09-25 2004-11-04 株式会社白子 海苔の酵素分解組成物およびその用途
AU6289699A (en) * 1998-10-05 2000-04-26 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
ATE465266T1 (de) * 1998-12-31 2010-05-15 Novartis Vaccines & Diagnostic Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
WO2000061772A2 (en) 1999-04-14 2000-10-19 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ATE324877T1 (de) 1999-08-17 2006-06-15 Purdue Research Foundation Behandlung von metastatischer krankheit
WO2001031046A1 (en) * 1999-10-26 2001-05-03 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
US6767699B2 (en) * 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002003917A2 (en) * 2000-07-07 2002-01-17 Alphavax, Inc. Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
ATE499948T1 (de) * 2001-01-12 2011-03-15 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
JP4608210B2 (ja) * 2001-05-31 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアルファウイルスレプリコン粒子
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
US6605947B2 (en) * 2001-10-03 2003-08-12 Yi-Chia Liao Cup shape sensible container for detecting liquid property
JP3857195B2 (ja) * 2002-07-09 2006-12-13 株式会社東芝 距離継電装置
ES2630222T3 (es) * 2002-12-13 2017-08-18 Alphavax, Inc. Partículas alfavíricas y métodos de preparación
JP4991108B2 (ja) * 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
CN1791678A (zh) 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines

Also Published As

Publication number Publication date
AU2005245956A1 (en) 2005-12-01
US20050266550A1 (en) 2005-12-01
DK1751289T3 (da) 2009-05-11
IL178917A (en) 2010-11-30
US9441247B2 (en) 2016-09-13
US20160348132A1 (en) 2016-12-01
NZ550818A (en) 2009-09-25
US9079943B2 (en) 2015-07-14
US8709441B2 (en) 2014-04-29
JP2007537761A (ja) 2007-12-27
US20110027306A1 (en) 2011-02-03
MXPA06013124A (es) 2007-05-23
IL178917A0 (en) 2007-03-08
AU2005245956B2 (en) 2011-05-19
CN1989250B (zh) 2013-11-20
CA2567254C (en) 2012-03-13
US20150299728A1 (en) 2015-10-22
EP1751289B1 (de) 2009-01-14
ZA200610561B (en) 2008-06-25
CN1989250A (zh) 2007-06-27
WO2005113782A1 (en) 2005-12-01
DE602005012382D1 (de) 2009-03-05
CA2567254A1 (en) 2005-12-01
ES2321212T3 (es) 2009-06-03
JP5065024B2 (ja) 2012-10-31
PT1751289E (pt) 2009-03-31
US20140205629A1 (en) 2014-07-24
US10570416B2 (en) 2020-02-25
EP1751289A1 (de) 2007-02-14

Similar Documents

Publication Publication Date Title
ATE420965T1 (de) Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
Mueller et al. Small-x physics beyond the Kovchegov equation
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
DE60135983D1 (de) Verfahren zur reinigung von alphaviralen replikon partikeln
DE602005014628D1 (de) Embolie-teilchen
MX2020011095A (es) Composiciones que tienen un deposito mejorado de agentes anticaspa solubles en surfactante.
SG165155A1 (en) Novel flavivirus antigens
MX361514B (es) Composiciones de limpieza para cuidado personal libres de sulfato.
DE60236864D1 (de) Chimere alphavirus-replikon-partikel
NZ717682A (en) Virus like particle composition
MX2019010404A (es) Compuestos sulfamida cíclicos y métodos de uso de los mismos.
WO2007081974A3 (en) Viral hepatitis treatment
PH12016502554B1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
ATE426412T1 (de) Adjuvante influenza-vakzine
SG156666A1 (en) Vaccines against japanese encephalitis virus and west nile virus
EA201891460A1 (ru) Композиция дендритных клеток
DK1375670T3 (da) Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
EA200701128A1 (ru) Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы
MX2017008363A (es) Composición cosmética de filtro solar.
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2010006984A (es) Vacunas contra la malaria.
ZA202100854B (en) Personal care compositions
WO2004005473A3 (en) Hcv fusion proteins with modified ns3 domains

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1751289

Country of ref document: EP